Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• Sinonasal teratocarcinosarcoma (TCS) is a rare malignancy with aggressive behavior and poor prognosis.
• Limited treatment options exist for TCS patients, necessitating novel therapeutic strategies.
• Recurrent SMARCA4 mutations have been identified in TCS, suggesting potential therapeutic targets.

Purpose of the Study:

• To establish and characterize the first in vitro cell line (TCS627) from a primary sinonasal teratocarcinosarcoma.
• To investigate the genetic landscape of TCS and identify potential therapeutic vulnerabilities.
• To evaluate the efficacy of targeted inhibitors against identified mutations in the TCS cell line.

Main Methods:

• Establishment of an in vitro cell line (TCS627) from a primary sinonasal teratocarcinosarcoma.
• Immunohistochemical analysis to confirm differentiation of various cellular components.
• Whole-exome sequencing to identify somatic mutations, including SMARCA4.
• In vitro growth inhibition assays using CDK4/6 and EZH1/2 inhibitors.

Main Results:

• The TCS627 cell line recapitulates the diverse histological and genetic features of sinonasal teratocarcinosarcoma.
• Whole-exome sequencing identified 99 somatic mutations, including alterations in SMARCA4, ARID2, TET2, CDKN2A, WNT7A, NOTCH3, and STAG2.
• The TCS627 cell line exhibited sensitivity to the CDK4/6 inhibitor palbociclib, but limited response to the EZH1/2 inhibitor valemetostat, suggesting SMARCA4 as a potential therapeutic target.

Conclusions:

• The TCS627 cell line is a valuable preclinical model for studying sinonasal teratocarcinosarcoma.
• Targeting SMARCA4 mutations with CDK4/6 inhibitors shows therapeutic potential for TCS.
• This model facilitates basic research and the development of novel treatment strategies for patients with sinonasal teratocarcinosarcoma.